Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

FCA Firm Checker campaign – Seal the deal
Use the FCA Firm Checker first to check a firm is authorised and genuine to help avoid scams.
DyGIST 2026: testing your readiness
The Prudential Regulatory Authority (PRA) has confirmed that the Dynamic General Insurance Stress Test (DyGIST) will start in May 2026. This isn’t the
New year renewed focus Construction Professional Indemnity
As we step into a new year, many of us are setting fresh objectives – both personal and professional. For those operating in the Construction Professi

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.